Claritev (MultiPlan) 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 total revenue was $268.3 million, up 9.1% year over year and 4.2% sequentially, marking the sixth consecutive quarter of year-over-year growth and the highest quarterly revenue in 17 quarters.
- Claims Intelligence revenue grew 17.1% year over year, primarily reflecting incremental NSA volumes associated with an early '26 client win; network revenue declined 5.6%, primarily due to $5.4 million of non-recurring revenue in Q3 last year.
- Payment and revenue integrity was slightly behind the company’s internal plan as the transition of a legacy clinical negotiations business to claims intelligence solutions more than offset the ramp from newer solutions, including Advanced Code Editing (ACE).
- Adjusted EBITDA was $162 million, up 4.4% year over year and 4% sequentially, with a 60.4% margin compared with 63.1% in Q3 last year.
- For the first 9 months, revenue was $770.5 million, up 7.2% year over year, and adjusted EBITDA was $464.7 million, up 3%, with a 60.3% margin.
- Trailing 12-month revenue exceeded $1 billion for the first time since Q1 of '23.
- Q3 operating cash flow was $18.1 million, free cash flow was a use of $25.8 million, and unlevered free cash flow was $104.4 million; adjusted cash conversion was 64.5%.
- For the first 9 months, operating cash flow increased 27% to $65 million and unlevered free cash flow increased 16% to $230.7 million; adjusted cash conversion was 50%, up 6 percentage points from 44% last year.
- Claritev ended Q3 with $10.1 million of unrestricted cash and $95 million drawn on its revolver; its net leverage ratio improved to 7.7 times, a 0.1 turn improvement compared with Q3 '25.
- Claritev booked $27 million of ACV in Q3, bringing year-to-date bookings to more than $100 million, compared with $67 million for the full year '25; it added 5 new client logos in the quarter and has added 46 net new clients over 2 years.
- Of year-to-date bookings, 78% came from existing clients and more than 50% came from verticals outside the core payer market, including 26% from TPA and another 25% primarily from provider, public sector, and international markets.
- P-Safe claims volumes increased 8% year over year and were flat sequentially; submitted charges grew 15%, and identified potential savings per claim increased more than 13% year over year.
- Management said P-Safe savings dollars eclipsed $5 billion for the first time in perhaps 4 or 5 years, with more than $1,500 of savings per claim.
- Q3 dispute initiations were up 75% over the same quarter last year, and Claritev said its performance was 8% better than the industry average.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for standing by, and welcome to the Claritev Corporation Third Quarter 2026 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you'd like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you'd like to withdraw your question, press star one again. Thank you. I'd now like to turn the call over to Todd Friedman, Head of Investor Relations. Todd, you may begin. Thanks, Rob.
Good morning, everyone, and welcome to Claritev's Third Quarter 2026 Earnings Call. Joining me today are Travis Dalton, President and Chief Executive Officer, and Doug Garis, Chief Financial Officer. During our call, we will refer to information included in the supplemental slide deck that is now available in the investors portion of our website, along with the Third Quarter 2026 earnings press release that was issued earlier this morning. Our remarks and responses to questions today include forward-looking statements. These forward-looking statements represent management's beliefs and expectations only as of the date of this call. Actual results may differ materially from these forward-looking statements due to a number of risks. A summary of these risks can be found on the second page of the supplemental slide deck and a more complete description in our annual report on Form 10-K and other documents we file with the SEC.
We will also be referring to several non-GAAP measures, which we believe provide investors with a more complete understanding of Claritev's underlying operating results. An explanation of these non-GAAP measures and reconciliations to their comparable GAAP measures can be found in the earnings press release and in the supplemental slide deck. With that, I now turn the call over to Travis.
Good morning, and thank you for joining us. Let me start by saying it was another strong quarter for Claritev. Simply put, we are delivering on the turn and the way up. Our horizontal product and vertical market strategy is working. Revenue and Adjusted EBITDA are ahead of guidance. Our growth teams are focused on execution, delivering ACV bookings across all verticals, and we are accelerating our innovation efforts to elevate how we serve our clients and deliver meaningful, measurable value. This progress was evident at our recent Claritev Client Conference. We are gaining momentum in the attendance, participation, and enthusiasm are building year-over-year. I will share more about this event later in the call.
Doug will provide more detail on the full financial results and our outlook, but we are a full year ahead of the plan that we laid out at our investor day earlier this year. On today's call, I'll cover a few key topics. First, our third quarter results and what is driving our success. Second, the innovation and market growth happening across Claritev, including surprise bill services momentum, recent new product launches, and our progress on AI. Finally, the strength of our competitive position and why we believe we are in great shape for a breakout 2027. Let me start with the results. Bookings, revenue, and Adjusted EBITDA all exceeded our expectations. Our performance reflects the same fundamentals we've emphasized throughout the year. Listening to our clients, focusing on their needs, and delivery excellence, we keep our promises.
This has allowed us to build on the trust we have with our clients and competitive advantages to diversify revenue growth, strengthen our vertical go-to-market strategy, and produce more product enhancements and features than ever before. It is clear that Claritev solves real and meaningful problems facing employees and constituents of healthcare. The clearest indicator of our momentum is bookings. We booked $27 million in ACV in the third quarter, bringing our year-to-date bookings to more than $100 million. We expect to finish 2026 with approximately 80% ACV growth over last year. Importantly, that growth is increasingly diversified. Bookings and pipeline are growing across every vertical market, reducing our reliance on any single market. While payer remains an important part of our business, public sector, provider, and TPA are all making meaningful contributions.
We added five new client logos in the quarter, bringing our two-year total to 46 net new clients, giving us growth from new relationships as well as deeper partnerships with existing clients. Our renewed focus on the TPA space is delivering results, and our overall pipeline remains strong and well-balanced across vertical markets. One of the most critical elements of our long-term vision is the diversification of our revenue base, and these results provide validation that our strategy is working and clients are turning to Claritev for more of their critical needs. Last quarter, we spoke about surprise bill services in the federal NSA business. NSA was once again a key driver in our outperformance, and we expect that tailwind will persist. Dispute initiations were up 75% in Q3 over the same quarter last year.
We continue to invest, focus, and apply our considerable talents and AI expertise in this area, which has allowed us to deliver 8% better performance than the industry average. Simply put, nobody does this better. I'm pleased with our performance and have great confidence that our growth teams will continue to perform and deliver a very strong close to our sales year to launch us into 2027. The innovation and expansion of our solutions and growing client momentum was on clear display at our annual Claritev Client Conference, which we held two weeks ago in Nashville. More than 100 clients joined together to hear about our vision and discuss the value Claritev is bringing to them. Most importantly, the event provided the opportunity for our team to hear from our clients on the issues and challenges that are most important to their businesses and their members.
We introduced a Medicare Advantage offering, bringing together more than 15 existing solutions across Payment & Revenue Integrity and Network to better support health plan clients serving the market. We also showcased a number of new innovations leveraging AI to improve the value we deliver, including Transparency-Based Pricing, our newest Claims Intelligence offering, and Claritev Healthcare Intelligence, one of our first examples of AI-native development. Transparency-Based Pricing combines massive sets of publicly available MRF data that is ingested and standardized using AI-enabled processes with our proprietary reimbursement intelligence to provide unique claim-level reference points. Some clients prefer to use an approach built off of the MRF data sets, and this is yet another option that offers flexibility for our clients when evaluating with our ProPricer tools the insights methodology that best suits their client needs. More tools, more flexibility, more opportunity to serve employees.
Claritev Healthcare Intelligence is a platform with a built-in AI agent, who we call Clara, that provides greater insights, cost trends, and drivers to better visualize and anticipate the critical insights that most impact a client's business. Historically, this type of analysis required weeks of manual work across disconnected data sources. We applied AI to the data we already have for our clients to put those insights into their hands in real time. This is an example of what only Claritev can do and what we have been saying on this call. We have trust, data, workflow, and years of expertise to give us a clear advantage in bringing solutions to the market. We will be sharing a demo with you of Clara in a few weeks to give you a sense of the innovation that our clients witnessed at the conference.
Together, these new solutions demonstrate how we are strengthening our core business, expanding into new market opportunities, and bringing meaningful innovation to our clients. They are also examples of our AI strategy, bringing together our decades-long claims expertise with AI-based data science and machine learning models to create new value for clients and new growth for us. None of this works without the foundation we have spent the last two years building, organized data and modern cloud workflows, harnessing our domain expertise. We see a powerful opportunity to create agentic workflows at lightning speed that can answer almost any challenge our customers face across all of our solutions. Today, we already have dozens of agents in production across the company, with many more in progress. Each one is built to take on a specific high-value task inside our workflow, and they are delivering results.
However, AI is only as powerful as the data, expertise, and the trust behind it. That is where Claritev stands apart. I will close with a few broader macro and landscape comments. The challenges facing access, affordability, and transparency persist. We are uniquely positioned, and it is in fact our mission to address these pressing problems. The need to tame medical inflation and rising costs has never been greater, and we play an important role in tackling these challenges across the healthcare ecosystem. I also think there is a real opportunity to change how solutions are scaled and bought in this segment of the market, giving operating expense savings to our clients that can then be passed on in the form of cost reduction to employees. Continued innovation and scale advantage can make an impact on costs over time. We bring more than four decades of experience.
We're a public company, transparent, and committed to long-term investments for our clients. We are not a widget or a point solution looking for an exit or a home. We offer proven solutions for our clients. In healthcare, those long relationships build trust. When you combine that trust with the ability to operate at scale and invest aggressively in AI and innovation, clients will turn to you to solve newer, harder, and more complex problems. This is what is ultimately driving our results and innovation agenda. We are laser-focused on access, Claims Intelligence, protecting employees, and bringing insights. Finally, let me close by saying we have used the words clarity, alignment, focus, and journey when describing our company, and others have called this a turnaround story. I think our Q3 results and the preliminary color we are providing on 2027 can only be described in one way.
Claritev is a growth company, period. Our performance last year and forecasts for the rest of 2026 and into 2027 demonstrate without qualification that we are solidly on a durable growth trajectory. It is evident in our numbers, it is evident in our culture, and it is evident in our confidence. Our competitive position has never been stronger. We're excited about a strong fourth quarter, and we are carrying that momentum into 2027. With that, I'll turn it over to Doug to walk through the financials in more detail.
Thank you, Travis, and good morning, everyone. In Q3, we once again outperformed our internal expectations for revenue, Adjusted EBITDA, and free cash flow, and we remain on track to deliver against the multi-year financial targets we outlined at Investor Day. I'll provide a few highlights on how we're thinking about 2027, but the punchline is we're running about a year ahead of the financial plan targets we outlined in March. Total revenue in the quarter was $268.3 million, up 9.1% year-over-year and 4.2% sequentially, well ahead of the roughly flat sequential cadence we suggested on our last call. This marks our sixth consecutive quarter of year-over-year revenue growth and our highest quarterly revenue in 17 quarters. Keep in mind that we have previously disclosed $18.6 million of non-recurring revenue last year that passed through Adjusted EBITDA at nearly 100% margin, with $5.4 million in Q3 and Q4.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
